Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Adults With Active Idiopathic Inflammatory Myopathy
2021-001277-23Phase 2Active
- Sponsor
- argenx
- Start
- Sep 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in Autoimmune Myopathies (2 arms), sponsored by argenx. Primary endpoint: Total improvement score (TIS). Started Sep 2022; status: active.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on 2021-001277-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001277-23.